Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2020, with a specific reporting date of April 16, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| April 14, 2020 | Ordinary Shares (25p each) | £15.6582 | 26 | Acquisition (Dividend Re-investment) |
| April 14, 2020 | Ordinary Shares (25p each) | £15.6582 | 30 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by two executives following the re-investment of dividends paid on April 9, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Executives Involved: Ms. V. Whyte (Company Secretary) and Mr. D. Redfern (Chief Strategy Officer).
- Transaction Nature: Both transactions were acquisitions of ordinary shares resulting from the re-investment of dividends within an Individual Savings Account (ISA).
- Market Data: Shares were acquired on the London Stock Exchange (XLON) at a price of £15.6582 per share.
- Volume: Ms. Whyte acquired 26 shares; Mr. Redfern acquired 30 shares.
- Financial Data: This filing does not provide quarterly or annual financial performance data.